MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges

gurufocus.com · 2026-09-09

On September 09, 2026, MannKind Corporation (NASDAQ: MNKD) announced a global licensing agreement with Rose Pharma to develop an inhaled GLP-1 therapy targeting

TickrTrends take: MNKD is currently classified as undervalued according to TickrTrends analysis within the Healthcare sector, which aligns with recent valuation assessments indicating significant upside potential. Investors focused on valuation metrics should monitor whether the company can address its profitability challenges, as sustained losses could pressure the stock even at discounted valuations. The gap between current market price and intrinsic value estimates may narrow if operational performance does not improve to support the underlying valuation thesis.

Read the full story at gurufocus.com →